1. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Issue 10370 (7th January 2023) Authors: Merola, Joseph F; Landewé, Robert; McInnes, Iain B; Mease, Philip J; Ritchlin, Christopher T; Tanaka, Yoshiya; Asahina, Akihiko; Behrens, Frank; Gladman, Dafna D; Gossec, Laure; Gottlieb, Alice B; Thaçi, Diamant; Warren, Richard B; Ink, Barbara; Assudani, Deepak; Bajracharya, Rajan; Shende, Vishv... Journal: Lancet Issue: Volume 401:Issue 10370(2023) Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Issue 10222 (8th February 2020) Authors: Ritchlin, Christopher T; Kavanaugh, Arthur; Merola, Joseph F; Schett, Georg; Scher, Jose U; Warren, Richard B; Gottlieb, Alice B; Assudani, Deepak; Bedford-Rice, Kathy; Coarse, Jason; Ink, Barbara; McInnes, Iain B Journal: Lancet Issue: Volume 395:Issue 10222(2019) Page Start: 427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Issue 10370 (7th January 2023) Authors: McInnes, Iain B; Asahina, Akihiko; Coates, Laura C; Landewé, Robert; Merola, Joseph F; Ritchlin, Christopher T; Tanaka, Yoshiya; Gossec, Laure; Gottlieb, Alice B; Warren, Richard B; Ink, Barbara; Assudani, Deepak; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Mease, Philip J Journal: Lancet Issue: Volume 401:Issue 10370(2023) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Challenges in Using Real‐World Clinical Practice Records for Retrospective Validation of Clinical Trial Data: Lessons Learned: 722. (October 2016) Authors: Kane, Sunanda V.; Afzali, Anita; Wolf, Doug; Shafran, Ira; Ciorba, Matthew A.; Ritter, Timothy E.; Sharaf, Mai; Fourment, Christopher; Kosutic, Gordana; Coarse, Jason; Randall, Charles W. Journal: American journal of gastroenterology Issue: Volume 111(2016)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Comparison of Cardiovascular Events in Elderly and Younger Crohn's Disease Patients Treated With Certolizumab Pegol: Results From a Pooled Safety Analysis: 1832. (October 2015) Authors: Ha, Christina; Choi, Jennifer; Katz, Seymour; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Hasan, Iram; Loftus, Edward V. Journal: American journal of gastroenterology Issue: Volume 110(2015)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Covariates Influencing the Exposure‐Response Relationship for Certolizumab Pegol During the Induction and Maintenances Phases in Patients with Crohn's Disease: 572. (October 2016) Authors: Casteele, Niels Vande; Feagan, Brian; Vermeire, Séverine; Yassine, Mohamed; Hasan, Iram; Coarse, Jason; Kosutic, Gordana; Sandborn, William J. Journal: American journal of gastroenterology Issue: Volume 111(2016)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Issue 5 (6th April 2020) Authors: van der Heijde, Désirée; Gensler, Lianne S; Deodhar, Atul; Baraliakos, Xenofon; Poddubnyy, Denis; Kivitz, Alan; Farmer, Mary Katherine; Baeten, Dominique; Goldammer, Nadine; Coarse, Jason; Oortgiesen, Marga; Dougados, Maxime Journal: Annals of the rheumatic diseases Issue: Volume 79:Issue 5(2020) Page Start: 595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. (1st December 2016) Authors: Melmed, Gil Y.; McGovern, Dermot; Schreiber, Stefan; Kosutic, Gordana; Spearman, Marshall; Coarse, Jason; Sandborn, William J. Journal: Current medical research and opinion Issue: Volume 32:Number 12(2016:Dec.) Page Start: 1937 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. (5th July 2022) Authors: Mease, Philip J; Asahina, Akihiko; Gladman, Dafna D; Tanaka, Yoshiya; Tillett, William; Ink, Barbara; Assudani, Deepak; de la Loge, Christine; Coarse, Jason; Eells, Jason; Gossec, Laure Journal: Rheumatology Issue: Volume 62:Number 2(2023) Page Start: 617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Issue 7 (13th April 2017) Authors: Sandborn, William J.; Wolf, Douglas C.; Kosutic, Gordana; Parker, Gerry; Schreiber, Stefan; Lee, Scott D.; Abraham, Bincy; Afzali, Anita; Arsenescu, Razvan I.; Gutierrez, Alexandra; Spearman, Marshall; Coarse, Jason; Feagan, Brian G. Journal: Inflammatory bowel diseases Issue: Volume 23:Issue 7(2017) Page Start: 1047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗